Rostock Group is interested in a new strategic investor for Skulachev’s Ions Project
With significant advancement of the Skulachev’s Ions Project in phase II clinical trials of eye drops for glaucoma and cataract, the early R&D stage of the Project development is considered completed.
Further Project realization depends mainly on meeting standards for later-stage clinical trials.
Further realization of the Project requires significant additional investments to complete clinical trials.
Rostock Group as an investor focused on supporting breakthrough projects on early stages of their development has accomplished its mission for the Project.
The Group’s investment strategy does not envisage financing projects in later stages. Therefore, Rostock Group is interested in a new strategic investor for Skulachev’s Ions Project for advancing the Project to its completion.
Please forward your requests of more detailed information to our e-mail: firstname.lastname@example.org. You will receive the full Project description and investment proposal.
Topic: Skulachev Ions